About DestiNA Genomics
DestiNA Genomics is a company based in Edinburgh (United Kingdom) founded in 2010 by Hugh Ilyine and Juan Jose Diaz Mochon.. DestiNA Genomics has raised $1.9 million across 11 funding rounds from investors including European Union. DestiNA Genomics offers products and services including Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis. DestiNA Genomics operates in a competitive market with competitors including NuProbe, Nanosphere, ATDBio, Marker Gene Technologies and LGC Biosearch Technologies, among others.
- Headquarter Edinburgh, United Kingdom
- Founders Hugh Ilyine, Juan Jose Diaz Mochon
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Destina Genomics Ltd
- Date of Incorporation 28 Apr, 2010
- Jurisdiction EDINBURGH
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.9 M (USD)
in 11 rounds
-
Latest Funding Round
$248.7 K (USD), Grant
Nov 01, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DestiNA Genomics
DestiNA Genomics offers a comprehensive portfolio of products and services, including Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Kits for nucleic acid testing and RNA detection in research.
Kit for detecting liver injury through miRNA profiling.
Method for direct quantification of miRNAs from body fluids.
Custom design and supply of peptide nucleic acids for clients.
Funding Insights of DestiNA Genomics
DestiNA Genomics has successfully raised a total of $1.9M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $248.7 thousand completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Grant — $248,701
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Grant - DestiNA Genomics | Valuation |
investors |
|
| Jan, 2021 | Amount | Grant - DestiNA Genomics | Valuation |
investors |
|
| Jan, 2019 | Amount | Grant - DestiNA Genomics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in DestiNA Genomics
DestiNA Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by DestiNA Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - DestiNA Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Destina Genomics Comparisons
Competitors of DestiNA Genomics
DestiNA Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NuProbe, Nanosphere, ATDBio, Marker Gene Technologies and LGC Biosearch Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Sensitive multiplex platforms for QPCR are developed using toehold probes.
|
|
| domain | founded_year | HQ Location |
Diagnostic tests for personalized medicine targeting infections are provided.
|
|
| domain | founded_year | HQ Location |
Developer of oligonucleotides
|
|
| domain | founded_year | HQ Location |
Develops kits and reagents for research application
|
|
| domain | founded_year | HQ Location |
Provider of genomic analysis tools, instrumentation and services
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Destina Genomics
Frequently Asked Questions about DestiNA Genomics
When was DestiNA Genomics founded?
DestiNA Genomics was founded in 2010.
Where is DestiNA Genomics located?
DestiNA Genomics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Who is the current CEO of DestiNA Genomics?
Hugh Ilyine is the current CEO of DestiNA Genomics. They have also founded this company.
Is DestiNA Genomics a funded company?
DestiNA Genomics is a funded company, having raised a total of $1.9M across 11 funding rounds to date. The company's 1st funding round was a Grant of $478.96K, raised on Oct 07, 2010.
What does DestiNA Genomics do?
DestiNA Genomics was founded in 2010 in Edinburgh, United Kingdom, within the genomics sector. Non-enzymatic detection technology is created through dynamic chemistry, featuring DGL probes that integrate aldehyde-modified nucleobases with peptide nucleic acid. Binding to target sequences is facilitated, leaving blanks at deletion or mutation sites to minimize false positives over enzymatic methods. Applications cover insertions, deletions, mutations, and non-mutated nucleic acid sequences.
Who are the top competitors of DestiNA Genomics?
DestiNA Genomics's top competitors include NuProbe, Nanosphere and ATDBio.
What products or services does DestiNA Genomics offer?
DestiNA Genomics offers Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis.
Who are DestiNA Genomics's investors?
DestiNA Genomics has 1 investor. Key investors include European Union.